Chlorodehydromethyltestosterone (CDMT; brand name Oral Turinabol), also known as 4-chloro-17β-hydroxy17α-methylandrosta-1,4-dien-3-one, is an anabolic–androgenic steroid (AAS). It is the 4-chloro-substituted derivative of metandienone (dehydromethyltestosterone).

Clinical data
Other names4-Chlordehydromethyltestosterone; Dehydrochloromethyltestosterone; 4-Chloromethandienone
  • AU: X (High risk)
Routes of
By mouth
Drug classAndrogen; anabolic steroid
Legal status
Legal status
Pharmacokinetic data
Elimination half-life16 hours[citation needed]
  • 4-Chloro-17α-methylandrosta-1,4-dien-17β-ol-3-one
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass334.88 g·mol−1
3D model (JSmol)
  • O=C1\C=C/[C@]4(/C(=C1/Cl)CC[C@@H]3[C@@H]4CC[C@]2([C@H]3CC[C@@]2(O)C)C)C
  • InChI=1S/C20H27ClO2/c1-18-9-8-16(22)17(21)15(18)5-4-12-13(18)6-10-19(2)14(12)7-11-20(19,3)23/h8-9,12-14,23H,4-7,10-11H2,1-3H3/t12-,13+,14+,18-,19+,20+/m1/s1 checkY
 ☒NcheckY (what is this?)  (verify)

Side effectsEdit


CDMT was the first original product of Jenapharm, an East German pharmaceutical company. The patent registration took place in 1961. The idea of combining the structures of 4-chlorotestosterone (clostebol) and metandienone originated from the chemist Albert Stachowiak.[citation needed] At the time this represented a unique dissociation of anabolic and androgenic effects after oral administration.[1] The product had been introduced for clinical use from 1965 until 1994 when its production was discontinued.

Society and cultureEdit

Doping in sportsEdit

CDMT was the key steroid administered to approximately 10,000 athletes from East Germany (GDR) as secret official policy, often without their knowing the nature of the "vitamins" they were forced to take. The doping program was run by the East German Government from about 1968 until 1989 when the GDR collapsed. The doping program was known as State Plan Topic 14.25. The doping was done in secret; it was only in the 1990s that Franke and Berendonk looked closely at the original archived information and discovered the true scope of just how well-planned and successful the doping regime had been (in terms of medal success and world record performances).[2]

Following allegations by the German documentary of widespread doping the IOC kicked off a reanalysis of Beijing 2008 and London 2012 samples for all sports.

In August 2017, UFC Light Heavyweight Champion Jon Jones tested positive for turinabol in a drug test administered by USADA following his victory over Daniel Cormier at UFC 214 the month prior.[3]

Weightlifters and sprinters in particular were found to have used CDMT. Most of the doped athletes coming from Russia, Ukraine, and Belarus.[4][unreliable source?] However,[clarification needed] the method developed by Grigory Rodchenkov in 2011[5] was used in 2016 to detect long-term metabolites of CDMT while retesting the athletes' Olympic samples.

Colorado Rockies third baseman Colton Welker tested positive in May of 2021 while playing for the Triple-A Albuquerque Isotopes. He was suspended 80 games.

See alsoEdit


  1. ^ Schwarz S, Onken D, Schubert A (July 1999). "The steroid story of Jenapharm: from the late 1940s to the early 1970s". Steroids. 64 (7): 439–45. doi:10.1016/S0039-128X(99)00003-3. PMID 10443899. S2CID 40156824.
  2. ^ Franke WW, Berendonk B (July 1997). "Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government". Clin. Chem. 43 (7): 1262–79. doi:10.1093/clinchem/43.7.1262. PMID 9216474. Archived from the original on 2011-05-14. Retrieved 2009-01-04.
  3. ^ "Jon Jones' B sample from UFC 214 also positive for steroid turinabol".
  4. ^ "Retests of Olympic Doping Samples *15 More Positives from 2008 Announced* - All Things Gym". All Things Gym. 2016-09-09. Retrieved 2016-12-31.
  5. ^ Sobolevsky T, Rodchenkov G (2012). "Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine". The Journal of Steroid Biochemistry and Molecular Biology. 128 (3–5): 121–7. doi:10.1016/j.jsbmb.2011.11.004. PMID 22142641. S2CID 42460280.